About this item:

60 Views | 49 Downloads

Author Notes:

Correspondence: A. R. Gonzalez, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (ramirezgonzaleza@who.int).

The findings, interpretations, and conclusions expressed in this article are those of the authors and do not necessarily reflect the policies or views of UNICEF, the WHO, the Bill and Melinda Gates Foundation, or the Centers for Disease Control and Prevention.

All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Subjects:

Research Funding:

This work was supported by the Bill and Melinda Gates Foundation (grant OPP1095024 to M. M. P., J. G., C. L. V., and S. W. and contracts to F. K. and H. E.).

This work is part of a supplement coordinated by the Task Force for Global Health with funding provided by The Bill and Melinda Gates Foundation and the Centers for Disease Control and Prevention.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Immunology
  • Infectious Diseases
  • Microbiology
  • Polio
  • eradication
  • poliovirus
  • endgame
  • OPV
  • oral polio vaccine
  • IPV
  • inactivated polio vaccine
  • ERADICATION
  • CESSATION

Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective

Show all authors Show less authors

Tools:

Journal Title:

Journal of Infectious Diseases

Volume:

Volume 216, Number suppl_1

Publisher:

, Pages S183-S192

Type of Work:

Article | Final Publisher PDF

Abstract:

In 2015, the Global Commission for the Certification of Polio Eradication certified the eradication of type 2 wild poliovirus, 1 of 3 wild poliovirus serotypes causing paralytic polio since the beginning of recorded history. This milestone was one of the key criteria prompting the Global Polio Eradication Initiative to begin withdrawal of oral polio vaccines (OPV), beginning with the type 2 component (OPV2), through a globally synchronized initiative in April and May 2016 that called for all OPV using countries and territories to simultaneously switch from use of trivalent OPV (tOPV; containing types 1, 2, and 3 poliovirus) to bivalent OPV (bOPV; containing types 1 and 3 poliovirus), thus withdrawing OPV2. Before the switch, immunization programs globally had been using approximately 2 billion tOPV doses per year to immunize hundreds of millions of children. Thus, the globally synchronized withdrawal of tOPV was an unprecedented achievement in immunization and was part of a crucial strategy for containment of polioviruses. Successful implementation of the switch called for intense global coordination during 2015-2016 on an unprecedented scale among global public health technical agencies and donors, vaccine manufacturers, regulatory agencies, World Health Organization (WHO) and United Nations Children's Fund (UNICEF) regional offices, and national governments. Priority activities included cessation of tOPV production and shipment, national inventories of tOPV, detailed forecasting of tOPV needs, bOPV licensing, scaling up of bOPV production and procurement, developing national operational switch plans, securing funding, establishing oversight and implementation committees and teams, training logisticians and health workers, fostering advocacy and communications, establishing monitoring and validation structures, and implementing waste management strategies. The WHO received confirmation that, by mid May 2016, all 155 countries and territories that had used OPV in 2015 had successfully withdrawn OPV2 by ceasing use of tOPV in their national immunization programs. This article provides an overview of the global efforts and challenges in successfully implementing this unprecedented global initiative, including (1) coordination and tracking of key global planning milestones, (2) guidance facilitating development of country specific plans, (3) challenges for planning and implementing the switch at the global level, and (4) best practices and lessons learned in meeting aggressive switch timelines. Lessons from this monumental public health achievement by countries and partners will likely be drawn upon when bOPV is withdrawn after polio eradication but also could be relevant for other global health initiatives with similarly complex mandates and accelerated timelines.

Copyright information:

© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 3.0 IGO License License (https://creativecommons.org/licenses/by/3.0/igo/).
Export to EndNote